Johnson & Johnson (NYSE:JNJ) Shares Sold by SMART Wealth LLC

SMART Wealth LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 21.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,698 shares of the company’s stock after selling 454 shares during the period. SMART Wealth LLC’s holdings in Johnson & Johnson were worth $246,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Global X Japan Co. Ltd. grew its position in Johnson & Johnson by 17.7% in the fourth quarter. Global X Japan Co. Ltd. now owns 3,178 shares of the company’s stock valued at $460,000 after acquiring an additional 478 shares in the last quarter. Prairie Wealth Advisors Inc. grew its holdings in Johnson & Johnson by 2.8% during the 4th quarter. Prairie Wealth Advisors Inc. now owns 3,061 shares of the company’s stock valued at $443,000 after purchasing an additional 84 shares in the last quarter. Beese Fulmer Investment Management Inc. increased its stake in Johnson & Johnson by 0.7% during the 4th quarter. Beese Fulmer Investment Management Inc. now owns 125,953 shares of the company’s stock worth $18,215,000 after buying an additional 869 shares during the period. Fairvoy Private Wealth LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at about $234,000. Finally, Keystone Financial Group Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $334,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Price Performance

Shares of JNJ opened at $154.22 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market cap of $371.31 billion, a P/E ratio of 23.19, a PEG ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock has a fifty day moving average price of $147.42 and a 200 day moving average price of $156.08.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.